A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 2 Study to Assess the Efficacy and Safety of Daily OM-85 Treatment vs. Placebo given in Children Aged 6 Months to 5 Years with Recurrent Wheezing

Phase: 2

Status: Ongoing

Details

This study aims to find out if the proposed study drug, OM-85, a marketed product in several countries worldwide but not in the US yet, helps make children’s recurrent wheezing better than other drugs or other types of treatments that are currently available and approved in the US market.

Sponsor: OM Pharma SA

NCT05857930 - IRB#2023-065

Sponsors

HOPE Cancer Center

Hope Cancer Center

Contact

Contact UT Clinical
Scroll to Top